UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000041259 |
|---|---|
| Receipt number | R000047074 |
| Scientific Title | Safety-verification trial about excessive intake of test beverage |
| Date of disclosure of the study information | 2021/08/04 |
| Last modified on | 2021/03/01 18:15:16 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Safety-verification trial about excessive intake of test beverage
Acronym
Safety-verification trial about excessive intake of test beverage
Scientific Title
Safety-verification trial about excessive intake of test beverage
Scientific Title:Acronym
Safety-verification trial about excessive intake of test beverage
Region
| Japan |
Condition
Condition
Healthy adults
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
In order to confirm whether an excessive intake of the test beverage could have sufficient safety.
Basic objectives2
Safety
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Incidence rates of some kind of adverse event and/or side effect
Key secondary outcomes
1. Physical measurement
2. Physiological test
3. Hematological test
4. Blood-biochemical test
5. General urinalysis
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Food |
Interventions/Control_1
Ingestion of the test beverage (3 bottles/day) to the subjects for 4 weeks.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 60 | years-old | > |
Gender
Male and Female
Key inclusion criteria
(1) Healthy male/female subjects ranging in age from 20 to 59 (including four subjects with some constipation tendency).
(2) Subjects who give informed consent to participate in this clinical trial after being provided with an explanation of our experimental protocol detail.
Key exclusion criteria
(1) Subjects with some kind of continuous medical treatment.
(2) Subjects with current and/or previous medical history of serious diseases in heart, liver, kidney and/or digestive organs.
(3) Subjects who have constantly used the following foods that might affect their blood glucose level, triglyceride level, and intestine-regulating function;
health-specific, functional, health foods.
(4) Subjects with excessive alcohol intake.
(5) Subjects with extremely irregular dietary habits and/or life rhythm.
(6) Pregnant or possibly pregnant women, or lactating ones.
(7) Subjects with drug and/or food allergy (especially in milk and soybean).
(8) Subjects with weak stomach and/or diarrhea-prone constitution.
(9) Subjects who are now under the other clinical tests with some kind of medicine/food, or participated those tests within four weeks after this clinical trial.
(10) Subjects who donated over 200 mL of their blood and/or blood components within a month to this clinical trial.
(11) Males who donated their whole blood (400 mL) within the last three months to this trial.
(12) Females who donated their whole blood (400 mL) within the last four months to this trial.
(13) Males who will be collected in total of their blood (1200 mL) within the last twelve months, after adding the blood amounts planning to be sampled in this trial.
(14) Females who will be collected in total of their blood (800 mL) within the last twelve months, after adding the blood amounts planning to be sampled in this trial.
(15) Others who have been determined as ineligible for participation in this trial, according to the principal/sub investigator's opinions.
Target sample size
16
Research contact person
Name of lead principal investigator
| 1st name | Suguru |
| Middle name | |
| Last name | Fujiwara |
Organization
CPCC Company Limited
Division name
Division of Clinical Research
Zip code
101-0047
Address
4F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan
TEL
03-5297-3112
cpcc-contact@cpcc.co.jp
Public contact
Name of contact person
| 1st name | Masanori |
| Middle name | |
| Last name | Numa |
Organization
CPCC Company Limited
Division name
Planning & Sales Department
Zip code
101-0047
Address
4F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan
TEL
03-5297-3112
Homepage URL
cpcc-contact@cpcc.co.jp
Sponsor or person
Institute
CPCC Company Limited
Institute
Department
Personal name
Funding Source
Organization
JAPAN SANGARIA BEVERAGE CO., LTD.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Institutional Review Board of Chiyoda Paramedical Care Clinic
Address
2F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan
Tel
03-5297-5548
IRB@cpcc.co.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2021 | Year | 08 | Month | 04 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2020 | Year | 07 | Month | 20 | Day |
Date of IRB
| 2020 | Year | 07 | Month | 17 | Day |
Anticipated trial start date
| 2020 | Year | 08 | Month | 04 | Day |
Last follow-up date
| 2020 | Year | 09 | Month | 29 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2020 | Year | 07 | Month | 30 | Day |
Last modified on
| 2021 | Year | 03 | Month | 01 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047074
